Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MIMETAS is at the forefront of organ-on-a-chip technology, dedicated to revolutionizing drug discovery and development. The company develops and commercializes the OrganoPlate®, a microfluidic platform that enables the creation of predictive 3D human tissue and disease models. These models are used by pharmaceutical companies, biotech firms, and academic institutions globally to improve the efficiency and translatability of preclinical research, ultimately aiming to bring better and safer medicines to patients faster. MIMETAS also offers contract research services and develops ready-to-use assay products.
Serves as the global headquarters, housing primary research and development labs, OrganoPlate® manufacturing facilities, global sales operations, and corporate administration.
Located within the Leiden Bio Science Park, known for its state-of-the-art laboratory facilities and a vibrant ecosystem of biotech companies and research institutions. The facility itself is likely equipped with advanced microfabrication and cell culture laboratories.
Fosters an innovative, collaborative, and scientifically-driven environment. Employees are passionate about advancing human health through cutting-edge technology and rigorous research. There's a strong emphasis on teamwork, agility, and pioneering solutions in the organ-on-a-chip field.
The Leiden headquarters is the birthplace and central nervous system of MIMETAS's pioneering work in organ-on-a-chip technology, driving product innovation, global strategy, and manufacturing of their core OrganoPlate® platform.
MIMETAS supports drug discovery and development globally through its innovative OrganoPlate® platform and associated products and services. Key functions supported globally include sales and distribution of OrganoPlates® and assay kits, contract research services utilizing their 3D tissue models, technical support for customers, and scientific collaborations with leading pharmaceutical companies, biotech firms, and academic institutions across Europe, North America, and Asia-Pacific.
J.H. Oortweg 19
Leiden
Zuid-Holland
The Netherlands
Address: 9600 Gudelsky Drive, Rockville, MD 20850, USA
To provide localized support and expand MIMETAS's footprint in the significant U.S. life sciences sector, facilitating closer engagement with key customers and partners.
Address: Shinkawa KS Bldg 4F, 1-3-2 Shinkawa, Chuo-ku, Tokyo 104-0033, Japan
To cater to the growing demand for organ-on-a-chip technology in Asia, enabling direct customer interaction, support, and market penetration in this key pharmaceutical and research hub.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MIMETAS' leadership includes:
MIMETAS has been backed by several prominent investors over the years, including:
Within the last 12 months (approx. May 2023 - May 2024), no major publicly announced executive hires or departures have been prominently featured for MIMETAS. The existing leadership team, which saw key appointments like Kristin Eales as CSO (January 2023) and Nienke Weijmar as CFO (November 2022) prior to this period, appears to be stable and guiding the company's growth.
Discover the tools MIMETAS uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
MIMETAS likely utilizes common professional email formats for its employees. Based on industry patterns and available data, primary formats include [first].[last]@mimetas.com or [first_initial][last]@mimetas.com.
[first].[last]@mimetas.com (e.g., j.joore@mimetas.com) or [first_initial][last]@mimetas.com (e.g., jjoore@mimetas.com)
Format
j.joore@mimetas.com
Example
85%
Success rate
mimetas.com • July 19, 2023
MIMETAS announced an extension of its collaboration with AstraZeneca to develop novel human immunocompetent kidney-on-a-chip models. The models will be used to investigate drug-induced kidney injury and to explore new therapeutic avenues for kidney diseases....more
mimetas.com • June 20, 2023
MIMETAS introduced its new Assay Ready product, Kidney Proximal Tubules in OrganoPlate®. This product provides researchers with ready-to-use 3D kidney models, simplifying adoption and accelerating research in nephrotoxicity and kidney disease....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MIMETAS, are just a search away.